DSGN Design Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DSGN

Price (delayed)

$12.36

Market cap

$773.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.18

Enterprise value

$762.63M

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 82
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 8
Highlights
DSGN's debt has surged by 84% year-on-year but it is down by 8% since the previous quarter
The quick ratio has contracted by 25% YoY and by 16% from the previous quarter
DSGN's net income is down by 12% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.designtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of DSGN

DSGN stock price

How has the Design Therapeutics stock price performed over time
Intraday
-6.08%
1 week
-1.16%
1 month
-17.55%
1 year
105.32%
YTD
31.77%
QTD
-14.58%

Financial performance

How have Design Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$79.36M
Net income
-$70.8M
Gross margin
N/A
Net margin
N/A
DSGN's net income is down by 12% YoY
DSGN's operating income is down by 6% year-on-year

Price vs fundamentals

How does DSGN's price correlate with its fundamentals

Growth

What is Design Therapeutics's growth rate over time

Valuation

What is Design Therapeutics stock price valuation
P/E
N/A
P/B
3.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 5% year-on-year
DSGN's P/B is 126% above its 5-year quarterly average of 1.8 and 36% above its last 4 quarters average of 3.0
Design Therapeutics's equity has decreased by 7% QoQ and by 5% YoY

Efficiency

How efficient is Design Therapeutics business performance
DSGN's ROE is down by 25% YoY and by 2.7% QoQ
Design Therapeutics's ROA has decreased by 23% YoY and by 2.6% from the previous quarter
The company's return on invested capital fell by 22% YoY

Dividends

What is DSGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DSGN.

Financial health

How did Design Therapeutics financials performed over time
DSGN's total liabilities is up by 35% YoY and by 7% QoQ
The quick ratio has contracted by 25% YoY and by 16% from the previous quarter
DSGN's debt is 99% smaller than its equity
DSGN's debt has surged by 84% year-on-year but it is down by 8% since the previous quarter
Design Therapeutics's equity has decreased by 7% QoQ and by 5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.